Full text is available at the source.
Abstract
Fecal microbiota transplantation (FMT) has emerged as a potential novel therapeutic tool to enhance immune checkpoint inhibitor response.
- Immune checkpoint inhibitors are changing treatment for genitourinary and other immune-responsive cancers.
- The gut microbiome may influence immune regulation and response to these therapies.
- Several trials suggest that FMT could improve responses to immune checkpoint inhibitors.
- While the safety and clinical potential of FMT are established, specific treatment regimens and protocols need further definition.
- Probiotic supplementation may also be a promising area for future investigation.
Simplified